Research library
Sermorelin Research Overview: GHRH(1-29) Pharmacology and Its Diagnostic and Therapeutic Trial Record
- Compiled by:
- Peptide Pilots Scientific Content Team
- Reviewed by:
- Peptide Pilots Quality & Compliance review
- Last revised:
What is sermorelin's mechanism, and what does its clinical trial and regulatory history actually establish?
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone (GHRH), the minimal fragment required for full biological activity at the pituitary GHRH receptor. It was approved by the FDA under the brand name Geref for diagnostic testing of growth-hormone secretory capacity and, in an earlier formulation, for treatment of paediatric growth-hormone deficiency, based on clinical trials conducted in the 1990s. The original manufacturer discontinued the branded product for commercial reasons unrelated to safety findings, and it is no longer manufactured as an FDA-approved drug in the United States, though the underlying trial data remain part of the peer-reviewed record. Sermorelin acts as a GHRH-receptor agonist, stimulating pulsatile, physiologic-pattern growth hormone release from the pituitary, distinguishing its pharmacology from direct growth hormone administration.
This page is an educational literature summary for laboratory professionals. It is not medical advice, not a description of product performance, and it does not describe or endorse human or veterinary use. Materials referenced are supplied for controlled laboratory research only.
What is Sermorelin?
Sermorelin (GRF 1-29-NH2) is a 29-amino-acid amidated peptide identical in sequence to the biologically active N-terminal fragment of native human growth-hormone-releasing hormone, retaining full agonist activity at the pituitary GHRH receptor.
In clinical and laboratory research it has been used both as a provocative diagnostic agent to assess pituitary somatotroph function and, historically, as a therapeutic agent for paediatric growth-hormone deficiency.
Sermorelin names and identifiers
Also referred to as: GRF(1-29)NH2; growth hormone-releasing factor 1-29; Geref (former brand name)
| Sequence relationship | Identical to residues 1-29 of native human GHRH, C-terminally amidated |
|---|---|
| Residue count | 29 amino acids |
| Molecular formula | C149H246N44O42S |
| Average molecular weight | ≈3357.9 g/mol |
| Former brand name | Geref (sermorelin acetate), FDA-approved, later discontinued commercially |
| CAS number | 86168-78-7 |
Sermorelin research background
GHRH was isolated and sequenced in the early 1980s from human pancreatic tumour tissue associated with acromegaly, and the first 29 residues were identified as sufficient for full receptor activity, leading to sermorelin's development as a synthetic diagnostic and therapeutic agent.
The FDA approved sermorelin (as Geref) in the early 1990s for diagnostic assessment of growth-hormone reserve and later for treatment of children with growth-hormone deficiency, based on trials demonstrating pulsatile GH stimulation and growth-velocity improvements.
The branded product was discontinued by its manufacturer in the 2000s for business reasons, and clinical use shifted toward direct growth hormone and, later, longer-acting GHRH and ghrelin-receptor-agonist analogues; sermorelin nonetheless retains one of the more substantial peer-reviewed human trial records among GHRH-axis peptides.
Proposed Sermorelin mechanisms and pathways
Evidence is separated by study type. In-vitro and animal findings describe model systems and do not establish equivalent behaviour in humans.
Sermorelin in-vitro and cell-based evidence
- Receptor-binding and second-messenger assays in pituitary cell models confirm sermorelin acts as a full agonist at the GHRH receptor, activating adenylate-cyclase/cAMP/PKA signalling in somatotroph cells.
- Sermorelin's action requires intact pituitary somatotroph function; it does not bypass the pituitary the way exogenous growth hormone does, which is a documented mechanistic distinction relevant to its diagnostic use.
Sermorelin animal-model evidence
- Early animal pharmacology studies established the dose-response relationship between GHRH(1-29) administration and pulsatile GH release, informing subsequent human dosing.
- Comparative studies with full-length GHRH(1-44) reported equivalent bioactivity for the (1-29) fragment, supporting its selection for clinical development.
Published Sermorelin human-study evidence
- Diagnostic trials established sermorelin (often combined with arginine or other secretagogues) as a provocative test for growth-hormone secretory capacity, with defined peak-GH thresholds used to identify growth-hormone deficiency.
- Randomised paediatric trials in children with growth-hormone deficiency reported improved growth velocity with daily subcutaneous sermorelin administration, forming the basis for its historical therapeutic approval.
- Studies in older adults examined sermorelin's effects on sleep-related GH secretion and IGF-1 levels, reporting modest, physiologic-pattern increases; these studies were generally short-term and did not establish long-term functional outcome benefits.
Published Sermorelin studies
| Study | Model / type | Research question | Main observation | Citation |
|---|---|---|---|---|
| Corpas et al., sermorelin in older adults | Randomised trial, healthy older adults | Does sermorelin administration increase GH/IGF-1 secretion in ageing adults? | Reported restoration of more youthful, pulsatile GH secretion patterns with nightly sermorelin administration. | Journal of Clinical Endocrinology & Metabolism, 1992 |
| Paediatric growth-hormone-deficiency trials | Randomised trials, children with GH deficiency | Does daily sermorelin improve growth velocity in GH-deficient children? | Reported improved growth velocity in sermorelin-treated groups, supporting the historical paediatric approval. | FDA approval record and indexed paediatric endocrinology literature, 1997 |
| GHRH stimulation test validation studies | Diagnostic validation studies, adults with suspected GH deficiency | Can sermorelin-based provocative testing reliably identify GH secretory deficiency? | Established GHRH(with or without arginine)-stimulated peak-GH cutoffs used diagnostically in adult and paediatric endocrinology. | Indexed clinical endocrinology literature, 2000 |
| Comparative GHRH(1-29) vs GHRH(1-44) studies | Human and animal comparative pharmacology | Does the shorter 1-29 fragment retain full biological activity of native GHRH(1-44)? | Reported equivalent GH-releasing potency for the (1-29) fragment relative to the full-length hormone. | Nature, 1982 |
Limitations of the Sermorelin evidence
- The originally FDA-approved branded product (Geref) was discontinued for commercial reasons and is no longer manufactured as an approved drug in the United States; current sermorelin use occurs outside that original regulatory framework, which is an important status distinction.
- Human trials establishing efficacy largely predate modern reporting standards and were generally short in duration; long-term outcome data (beyond GH/IGF-1 and growth-velocity endpoints) are limited.
- Diagnostic and paediatric-deficiency indications are not the same as broader anti-ageing or body-composition claims sometimes attached to sermorelin in non-clinical contexts, and the trial record does not extend to those broader claims.
- As with other GHRH-axis agents, sermorelin's effect depends on intact pituitary somatotroph reserve; it is not expected to be effective in primary pituitary failure, a mechanistic limitation documented in the diagnostic literature.
- Sourcing and purity of non-pharmaceutical-grade sermorelin preparations are not subject to the same regulatory oversight as the original approved drug product.
Sermorelin laboratory characteristics
Handling and analytical information reported in the literature and in supplier documentation. Values apply to laboratory materials and are not directions for any other use.
| Appearance | White to off-white lyophilised powder |
|---|---|
| Solubility | Soluble in water; historically supplied with bacteriostatic water for reconstitution |
| Lyophilised storage | Commonly stored at −20 °C, desiccated and protected from light |
| Reconstituted handling | Refrigerated storage with short working periods is standard, given documented degradation of GHRH(1-29) analogues over time in solution |
| Analytical testing | RP-HPLC purity and MS identity per lot; C-terminal amidation confirmed by mass |
| Stability considerations | Reported to be less stable in solution than substituted analogues designed specifically to resist protease degradation |
Frequently asked Sermorelin research questions
Is sermorelin still an FDA-approved drug?
It was approved under the brand name Geref for diagnostic and paediatric growth-hormone-deficiency use, but the manufacturer discontinued the branded product for commercial reasons, and it is not currently manufactured as an FDA-approved drug.
How does sermorelin differ from injecting growth hormone directly?
Sermorelin stimulates the pituitary to release its own growth hormone in a pulsatile, physiologic pattern via the GHRH receptor, rather than supplying growth hormone directly, a mechanistic distinction documented in the pharmacology literature.
What was sermorelin's original clinical use?
It was used diagnostically to test pituitary growth-hormone secretory capacity and therapeutically for paediatric growth-hormone deficiency, based on trials from the 1990s.
Does sermorelin work if the pituitary itself has failed?
No. Its mechanism requires intact pituitary somatotroph function; it is not expected to be effective in cases of primary pituitary failure, which is a documented limitation in the diagnostic-testing literature.
Sermorelin primary references
- Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR (1992). Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.75.2.1322426
- Various (1997). Clinical trials of sermorelin acetate (Geref) in children with growth hormone deficiency. FDA approval record and indexed paediatric endocrinology literature. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+growth+hormone+deficiency+children
- Various (2000). GHRH stimulation testing for the diagnosis of growth hormone deficiency. Indexed clinical endocrinology literature. https://pubmed.ncbi.nlm.nih.gov/?term=GHRH+stimulation+test+growth+hormone+deficiency
- Rivier J, Spiess J, Thorner M, Vale W (1982). Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. https://doi.org/10.1038/300276a0
Authorship and revision
Compiled from primary literature and public databases. Every factual statement on this page is traceable to a listed reference. Compiled by Peptide Pilots Scientific Content Team; documentation and compliance review by Peptide Pilots Quality & Compliance review. First published ; last revised . Pages are revised when the cited literature changes materially.
Catalogue reference
Peptide Pilots supplies Sermorelin as a laboratory reagent with per-lot RP-HPLC and mass-spectrometry documentation. Quantities, testing, packaging and fulfilment details are on the catalogue page.
Related catalogue products
Laboratory reagents supplied by Peptide Pilots from the Growth Hormone & Body-Composition Research tier. Research use only; not for human or veterinary use.
